Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy

被引：83

作者：

Rey, Sergio ^{[1
]}

Schito, Luana ^{[1
]}

Wouters, Bradly G. ^{[1
,2
,3
]}

Eliasof, Scott ^{[4
]}

Kerbel, Robert S. ^{[3
,5
]}

机构：

[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada

[3] Univ Toronto, Radiat Oncol, Toronto, ON, Canada

[4] Cerulean Pharma Inc, Waltham, MA USA

[5] Sunnybrook Res Inst, Biol Sci Platform, Toronto, ON, Canada

来源：

TRENDS IN CANCER | 2017年 / 3卷 / 07期

关键词：

NANOPARTICLE-DRUG CONJUGATE; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; VESSEL CO-OPTION; ANTI-ANGIOGENIC THERAPY; ORAL TOPOTECAN; BREAST-CANCER; METRONOMIC TOPOTECAN; TUMOR MICROENVIRONMENT; VASCULOGENIC MIMICRY;

D O I：

10.1016/j.trecan.2017.05.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hypoxia (low O-2) is a pathobiological hallmark of solid cancers, resulting from the imbalance between cellular O-2 consumption and availability. Hypoxic cancer cells (CCs) stimulate blood vessel sprouting (angiogenesis), aimed at restoring O-2 delivery to the expanding tumor masses through the activation of a transcriptional program mediated by hypoxia-inducible factors (HIFs). Here, we review recent data suggesting that the efficacy of antiangiogenic (AA) therapies is limited in some circumstances by HIF-dependent compensatory responses to increased intratumoral hypoxia. In lieu of this evidence, we discuss the potential of targeting HIFs as a strategy to overcome these instances of AA therapy resistance.

引用

页码：529 / 541

页数：13

共 50 条

[1] Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, Caroline
Pahlman, Sven
Bexell, Daniel
[J]. PHARMACOLOGY & THERAPEUTICS, 2016, 164 : 152 - 169
[2] Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, Saba Musleh Ud
Streit, Spencer G.
Huynh, Bao Tran
Hana, Caroline
Abraham, Anna-Ninny
Hussein, Atif
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
[3] Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review
Luo, Shuang
Jiang, Yu
Zheng, Anfu
Zhao, Yueshui
Wu, Xu
Li, Mingxing
Du, Fukuan
Chen, Yu
Deng, Shuai
Chen, Meijuan
Li, Wanping
Li, Xiaobing
Gu, Li
Sun, Yuhong
Xiao, Zhangang
Shen, Jing
[J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
[4] Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (Review)
Blagosklonny, MV
[J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 19 (02) : 257 - 262
[5] Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, Gregg L.
[J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59, 2019, 59 : 379 - 403
[6] Hypoxia-inducible factors and cancer
M. J. Calzada
L. del Peso
[J]. Clinical and Translational Oncology, 2007, 9 : 278 - 289
[7] Hypoxia-Inducible Factors and Cancer
Jun J.C.
Rathore A.
Younas H.
Gilkes D.
Polotsky V.Y.
[J]. Current Sleep Medicine Reports, 2017, 3 (1) : 1 - 10
[8] Hypoxia-Inducible Factors in Cancer
Kim, Laura C.
Simon, M. Celeste
[J]. CANCER RESEARCH, 2022, 82 (02) : 195 - 196
[9] Hypoxia-inducible factors and cancer
Calzada, M. J.
del Peso, L.
[J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (05): : 278 - 289
[10] Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Li, Y.
Ye, D.
[J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (07) : 782 - 796

← 1 2 3 4 5 →